Hemostemix Announces Positive Results and Conclusions Reported in Phase II CLI Trial Abstract – GlobeNewswire
By daniellenierenberg
CALGARY, Alberta, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (Hemostemix or the Company) (TSX VENTURE: HEM; OTCQB: HMTXF), a biotechnology company developing and commercializing blood-derived stem cell therapies for unmet medical conditions, is pleased to provide a summary of the presentation entitled Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Followup. Lead investigator Dr. York Hsiang, Professor of Vascular Surgery, University of British Columbia gave this update at the 41st Annual Canadian Society for Vascular Surgery Meeting on September 14, 2019.
Dr. Hsiang reported on the blinded results from the long-term follow-up of the first cohort of patients enrolled at two trial sites, Vancouver Coastal Health Research Institute (VCHRI) located in Vancouver, BC, led by principal investigator, Dr. York N. Hsiang, MB, ChB, MHSc, FRCSC and University Health Network, Peter Monk Cardiac Centre located in Toronto, Ontario, led by principal investigator Dr. Thomas Lindsay, MDCM, MSc, FRCSC, FACS.
Following is a summary of the results and conclusion:
In addition, the Companys Data Safety Monitoring Board (DSMB) recently met to review patient safety data in the ongoing Phase II clinical trial for CLI. The DSMB did not find safety concerns with ACP-01 and recommended continuing to enroll patients in the trial. The clinical trial is ongoing at 13 clinical sites in the US and Canada, with several additional sites in the process of being initiated. To date, 46 of the planned 95 patients have been enrolled and treated in the study.
We are very pleased with these blinded long term follow up results, and the recommendation of the DSMB, which are consistent with the findings reported in our two previous published studies of ACP-01 in CLI patients, said Dr. Alan Jacobs, President and Chief Medical Officer of Hemostemix. Patients with critical limb ischemia face a high rate of amputation when revascularization treatment options are exhausted, so seeing this level of improvement, and outcomes maintained for up to 4.5 years after treatment, is extremely encouraging.
ABOUT HEMOSTEMIX INC.
Hemostemix is a publicly traded clinical-stage biotechnology company that develops and commercializes innovative blood-derived cell therapies for medical conditions not adequately addressed by current treatments. It is one of the first clinical-stage biotech companies to test a stem-cell therapy in an international, multicenter, Phase II clinical trial for patients with critical limb ischemia (CLI), a severe form of peripheral artery disease (PAD) caused by reduced blood flow to the legs. The Phase II trial targets a participants diseased tissue with proprietary cells grown from his or her blood that can support the formation of new blood vessels. The Companys intellectual property portfolio includes over 50 patents issued or pending throughout the world. Hemostemix has a manufacturing contract with Aspire Health Science, LLC (Aspire), for the production of ACP-01 and for research and development purposes at Aspires Orlando, Florida, facility. Building towards commercialization, Hemostemix has also licensed the use, sale and import of ACP-01 for certain indications to Aspire in certain jurisdictions. The Company is continuing research and development of its lead product, ACP-01 with other applications, including cardiovascular, neurological and vascular indications.
For more information, please visit http://www.hemostemix.comor email office@hemostemix.com.
Contact:
Kyle Makofka, CEOSuite 2150, 300 5th Avenue S.W.Calgary, Alberta T2P 3C4Phone: (403) 506-3373E-Mail: kmakofka@hemostemix.com
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words expects, plans, anticipates, believes, intends, estimates, projects, potential, and similar expressions, or that events or conditions will, would, may, could, or should occur. Although Hemostemix believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Hemostemix management on the date such statements were made. By their nature forward-looking statements are subject to known and unknown risks, uncertainties, and other factors which may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the Companys stage of development, future clinical trial results, long-term capital requirements and future ability to fund operations, future developments in the Companys markets and the markets in which it expects to compete, risks associated with its strategic alliances and the impact of entering new markets on the Companys operations. Each factor should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise.
Read this article:
Hemostemix Announces Positive Results and Conclusions Reported in Phase II CLI Trial Abstract - GlobeNewswire
- Your Apple smartwatch may be the key to detecting heart issues before they happen - Massive Science - December 10th, 2019
- MarketsandMarkets 4th Annual Bioprocessing of Advanced Cellular Therapies & Regenerative Medicine Congress - Galus Australis - December 9th, 2019
- AgeX Therapeutics Issues Year-End Letter to Shareholders - BioSpace - December 9th, 2019
- Autologous Stem Cell and Non-Stem Cell Based Therapies Market share, size, opportunities, producers, growth factors by 2026 - Health Opinion - December 9th, 2019
- The Ins and Outs of Organ Donation - The Wire - December 9th, 2019
- Meditation increases blood flow in the heart, PET scans show - Health Imaging - December 8th, 2019
- With another $26M, Japan's Heartseed aims to advance iPSC-derived regenerative medicine for heart failure - BioWorld Online - December 8th, 2019
- CALQUENCE Significantly Prolonged the Time Patients Lived Without Disease Progression or Death in Previously Untreated Chronic Lymphocytic Leukemia -... - December 8th, 2019
- PHATED to be: Yale researchers give shape to big data - Yale News - December 6th, 2019
- Spinning Disk Confocal Microscope Market Growth Fueled by Reviving Techniques to Treat Heart Failure with Cardiac Regenerative Medicine - MENAFN.COM - December 6th, 2019
- Stem Cell Therapy Market Robust pace of Industry during 2017-2025 - News Description - December 6th, 2019
- Year in Review: Respiratory Infection - MedPage Today - December 6th, 2019
- MarketsandMarkets - 4th Annual Bioprocessing of Advanced Cellular Therapies & Regenerative Medicine Congress - Hitz Dairies - December 6th, 2019
- Global Synthetic Stem Cells Market :Industry Analysis and Forecast (2018-2026) - The Market Expedition - December 3rd, 2019
- Professor Recognized For Cardiac Regeneration Research - WPI News - December 3rd, 2019
- Stem cells may trigger immune repair to mend hearts - BioNews - December 2nd, 2019
- Stem cells do help restore heart function but in a different way - News-Medical.net - November 29th, 2019
- Can intermittent fasting help you live long? - Times of India - November 29th, 2019
- Novoheart to Co-develop First of its Kind Human Heart-in-a-Jar Model of Heart Failure with AstraZeneca - GlobeNewswire - November 29th, 2019
- Toddler Bravely Cheats Death After He Survived Rare Cancer And Its Treatment - The Digital Weekly - November 29th, 2019
- South Carolina toddler survives rare cancer and the risky procedure used to treat it - USA TODAY - November 28th, 2019
- Novoheart to Co-develop First of its Kind Human Heart-in-a-Jar Model of Heart Failure with AstraZene - PharmiWeb.com - November 28th, 2019
- Stem cells don't repair injured hearts, but inflammation might, study finds - FierceBiotech - November 28th, 2019
- Stem Cell Therapy May Improve Heart Health In New Ways - TheHealthMania - November 28th, 2019
- 'My daughter's death took me to the darkest place, but I've learned it's possible to come back' - Telegraph.co.uk - November 28th, 2019
- Stem Cell Assay Market Demand with Leading Key Players and New Investment Opportunities Emerge To Augment Segments in Sector By 2025 - The Denton... - November 28th, 2019
- Activation of the Immune System Underlies Cardiac Cell Therapies - The Scientist - November 27th, 2019
- Cell Separation Technology Market Size Projected to Rise Lucratively During 2019 2027 - News Description - November 27th, 2019
- Merck's KEYTRUDA (pembrolizumab) Now Approved in China for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) in... - November 26th, 2019
- Trump is blocking vital biomedical research - CNN - November 26th, 2019
- Stem Cell Therapy Market Segmentation, Assessment and Growth Opportunities by Forecast 2025 - Tech Admirers - November 26th, 2019
- Stem Cells For Heart Health: What The Current Research ... - November 25th, 2019
- Cardiol Therapeutics Announces Clinical Steering Committee for Phase 2 International Trial in Acute Myocarditis Using CardiolRx(TM) 100 | INN -... - November 25th, 2019
- Biobots are hybrid machines that have muscles and nerves - DesignNews - November 23rd, 2019
- CALQUENCE Approved in the US for Adult Patients With Chronic Lymphocytic Leukemia - Business Wire - November 23rd, 2019
- Suspended animation induced in humans for the first time - CNET - November 22nd, 2019
- AbbVie to Present Latest Clinical Research in the Treatment of Leukemias, Lymphomas and Other Blood Cancers at 2019 ASH Annual Meeting - P&T Community - November 22nd, 2019
- Cell Separation Technology Market Growth Forecast through 2019-2027 with Upcoming Trends and Market Opportunities - Montana Ledger - November 22nd, 2019
- CALQUENCE Approved in the US for Adult Patients With Chronic Lymphocytic Leukemia - BioSpace - November 22nd, 2019
- Cell Separation Technology Market is Expected To Elevate To a Stellar Value of US$ 2.7 Bn by 2027 - Downey Magazine - November 22nd, 2019
- Breaking News: Cardiol Therapeutics Announces Clinical Steering Committee for Phase 2 International Trial in Acute Myocarditis Using CardiolRx(TM) 100... - November 20th, 2019
- Stem Cell Therapy Market to Surge at a Robust Pace in Terms of Revenue Over 2025 - The Denton Chronicle - November 20th, 2019
- European Commission Approves Two New Regimens of Merck's KEYTRUDA (pembrolizumab) as First-Line Treatment for Metastatic or Unresectable Recurrent... - November 20th, 2019
- Validea's Top Five Healthcare Stocks Based On Motley Fool - 11/17/2019 - Nasdaq - November 18th, 2019
- Human heart cells behave differently in space - SellRegular - November 18th, 2019
- New cell therapy improves memory and stops seizures following TBI: Study - ANI News - November 17th, 2019
- Celgene Receives CHMP Positive Opinion for REVLIMID (lenalidomide) in Combination With Rituximab for the Treatment of Adult Patients With Previously... - November 15th, 2019
- The Heart of the Matter: Leveraging Advances in Cardiac Biology to Innovate Gene-Based Therapies for Heart Failure - Physician's Weekly - November 14th, 2019
- Human Heart Cells Transform in Space; Return to Normal on Earth: Study - The Weather Channel - November 14th, 2019
- Human Heart Cells Alter In Spaceflight But Return To Normal Quickly On Earth - Pragativadi - November 12th, 2019
- Financial Contrast: BioRestorative Therapies (OTCMKTS:BRTX) and Livongo Health (OTCMKTS:LVGO) - DFS Caller - November 12th, 2019
- Stem Cell Therapy Market Poised to Expand at a Robust Pace Over 2025 - Tech Admirers - November 11th, 2019
- Dystrogen Therapeutics Announces That Treatment With DEC Cells Improves Cardiac Function Cardiology2.0 - Cardiology2.0 - November 11th, 2019
- Reviewing US Stem Cell (OTCMKTS:USRM) and Auxly Cannabis Group (OTCMKTS:CBWTF) - Riverton Roll - November 11th, 2019
- Going into Space Changes the Human Heart Cells, but What Happens When They Get Back on Earth? - Henri Le Chat Noir - November 10th, 2019
- Dr Eilish McLoughlin honoured by SFI for Outstanding Contribution to STEM Communication - Dublin City University - November 9th, 2019
- Space travel affects heart cells, but only temporarily - BBC Focus Magazine - November 9th, 2019
- Teva and Celltrion Announce the Availability of TRUXIMA (rituximab-abbs) Injection, the First Biosimilar to Rituxan (rituximab) in the United States -... - November 8th, 2019
- Takeda to Highlight Expanded Portfolio of Products Across Oncology and Hematology at 61st American Society of Hematology (ASH) Annual Meeting -... - November 8th, 2019
- bluebird bio to Present New Data from Gene and Cell Therapy Programs at 61st American Society of Hematology Annual Meeting and Exposition - Financial... - November 6th, 2019
- Reviewing Capricor Therapeutics Inc. (CAPR)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - FinanceMercury - November 6th, 2019
- Dystrogen Therapeutics Announces That Treatment With Dystrophin Expressing Chimeric (DEC) Cells Improves Cardiac Function in Preclinical Duchenne's... - November 5th, 2019
- Future Outlook: Autologous Stem Cell Based Therapies Market Prediction and Analysis Offered By New Study 2019 2025: Leading Key Players: JCR... - November 5th, 2019
- Head-To-Head Analysis: BioRestorative Therapies (OTCMKTS:BRTX) versus Livongo Health (OTCMKTS:LVGO) - Casper Courier - November 5th, 2019
- Latest Released Report on Autologous Stem Cell Based Therapies Market to Witness the Highest Growth Globally in Coming Years: Osiris... - November 3rd, 2019
- InGeneron Announces Publication of Preclinical Results for its Cell Therapy in Chronic Ischemic Heart Failure - Business Wire - November 1st, 2019
- The Stars in Our Brains - Duke Department of Neurology - October 30th, 2019
- Global Cell Based Assay & High Content Screening Markets, 2020-2024 | Forecast by Application with Executive & Consultant Guides -... - October 30th, 2019
- Michael Schumacher: Has the racing champ recovered? Stem Cell Therapy doctor unknowingly confirmed Schumi's procedure? - EconoTimes - October 28th, 2019
- Regenerative Medicine Market Industry Outlook, Growth Prospects and Key Opportunities - Health News Office - October 25th, 2019
- Plant of the week: Plant thought to boost milk production now used for skin eruptions - Cyprus Mail - October 25th, 2019
- BioRestorative Therapies Receives A Second Patent in Australia For Its Metabolic Program - Yahoo Finance - October 23rd, 2019
- Bayer Announces Recipients of the Pulmonary Hypertension Accelerated Bayer (PHAB) Awards at CHEST Annual Meeting 2019 - PRNewswire - October 22nd, 2019
- Hemostemix Announces Positive Results and Conclusions Reported in Phase II CLI Trial Abstract - Yahoo Finance - October 22nd, 2019
- Best Growth Report On Autologous Stem Cell Based Therapies Market Survey 2019 Industry Outlines, Future Trends, Forecasts And Regional Segmented... - October 21st, 2019
- Bayer Announces Recipients of the Pulmonary Hypertension Accelerated Bayer (PHAB) Awards at CHEST Annual Meeting 2019 - BioSpace - October 21st, 2019
- Drug Treats Inflammation Related to Genetic Heart Disease - Technology Networks - October 18th, 2019
- Analysis on Worldwide Autologous Stem Cell Based Therapies Market Inclinations Exhibit Growing Demand During The Period Until 2025 - Wheel Chronicle - October 18th, 2019
- Sphingosine 1-phosphate: Lipid signaling in pathology and therapy - Science Magazine - October 18th, 2019
- Research Roundup: Genomic Dark Matter Mutation and More - BioSpace - October 18th, 2019
